About MaxCyte, Inc.
https://maxcyte.comMaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies.
CEO
Maher Masoud
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 52
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:9.98M
Value:$12.78M
CADIAN CAPITAL MANAGEMENT, LP
Shares:8.23M
Value:$10.53M
MIRABELLA FINANCIAL SERVICES LLP
Shares:8.2M
Value:$10.5M
Summary
Showing Top 3 of 126
About MaxCyte, Inc.
https://maxcyte.comMaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $6.83M ▼ | $16.89M ▼ | $-12.42M ▼ | -181.81% ▼ | $-0.12 | $-11.57M ▲ |
| Q2-2025 | $8.51M ▼ | $21.21M ▲ | $-12.36M ▼ | -145.26% ▼ | $-0.12 ▼ | $-12.93M ▼ |
| Q1-2025 | $10.39M ▲ | $21.19M ▲ | $-10.26M ▲ | -98.76% ▲ | $-0.1 | $-11.02M ▲ |
| Q4-2024 | $8.69M ▲ | $19.31M ▼ | $-10.6M ▲ | -121.9% ▲ | $-0.1 ▲ | $-11.37M ▲ |
| Q3-2024 | $8.16M | $20.29M | $-11.56M | -141.56% | $-0.11 | $-12.99M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $105.73M ▼ | $213.48M ▼ | $33.2M ▲ | $180.28M ▼ |
| Q2-2025 | $126.56M ▼ | $219.75M ▼ | $29.03M ▼ | $190.72M ▼ |
| Q1-2025 | $138.27M ▼ | $229.96M ▼ | $30.55M ▼ | $199.41M ▼ |
| Q4-2024 | $154.48M ▲ | $239.47M ▼ | $33.22M ▼ | $206.25M ▼ |
| Q3-2024 | $153.83M | $248.61M | $35.31M | $213.3M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-12.42M ▼ | $-7.46M ▲ | $5.19M ▲ | $14K ▼ | $-2.25M ▲ | $-7.76M ▲ |
| Q2-2025 | $-12.36M ▼ | $-9.85M ▲ | $1.54M ▼ | $154K ▼ | $-8.16M ▼ | $-10.44M ▲ |
| Q1-2025 | $-10.26M ▲ | $-14.41M ▼ | $9.53M ▲ | $383K ▼ | $-4.5M ▲ | $-15.06M ▼ |
| Q4-2024 | $-10.6M ▲ | $-7.82M ▼ | $-1.67M ▼ | $412K ▲ | $-9.07M ▼ | $-7.97M ▼ |
| Q3-2024 | $-11.56M | $-4.39M | $3.61M | $228K | $-555K | $-4.8M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $0 ▼ |
 Product and Service Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $0 ▲ | $10.00M ▲ | $10.00M ▲ |
CEO
Maher Masoud
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 52
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:9.98M
Value:$12.78M
CADIAN CAPITAL MANAGEMENT, LP
Shares:8.23M
Value:$10.53M
MIRABELLA FINANCIAL SERVICES LLP
Shares:8.2M
Value:$10.5M
Summary
Showing Top 3 of 126